Amycretin vs CagriSema
How Amycretin and CagriSema compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Amycretin and CagriSema come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Amycretin vs CagriSema, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Amycretin | CagriSema |
|---|---|---|
| What it is | Unimolecular GLP-1 and amylin receptor agonist (one synthetic peptide designed to activate both appetite-regulating pathways) | Fixed-dose combination of two peptides: cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Chronic weight management; Type 2 diabetes | Weight loss / obesity; Type 2 diabetes (blood-sugar control); Cardiovascular risk reduction (trial ongoing) |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 30 |
| Banned in sport (WADA) | Unknown | No |
| Key risks | Amycretin has randomized human safety data, but the published trials were early, small, single-center studies sponsored by Novo Nordisk. Gastrointestinal events, especially nausea, vomiting, and diarrhea, were frequent and increased with dose. Most reported events were mild or moderate, but withdrawals were numerous in the subcutaneous study. Long-term safety is not established. | Unlike most research peptides on this site, CagriSema has substantial human safety data — thousands of participants across the REDEFINE Phase 3 program. The side-effect profile is dominated by gastrointestinal effects (nausea, vomiting, diarrhea, constipation) typical of the GLP-1 and amylin classes, mostly during dose escalation. Long-term (multi-year) safety and the cardiovascular-outcomes trial are still reading out. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.Dahl et al., 2025 — subcutaneous amycretin Phase 1b/2a trial (The Lancet)
- 2.Gasiorek et al., 2025 — oral amycretin first-in-human Phase 1 trial (The Lancet)
- 3.AMAZE 12 Phase 3 amycretin weight-maintenance trial (NCT07503210)
- 4.FDA Novel Drug Approvals for 2026
- 5.USADA — 2026 WADA Prohibited List and investigational-drug guidance
- 6.CagriSema — indexed research (PubMed, National Library of Medicine)